Traitement pharmacologique du diabète de type 2 après chirurgie bariatrique/métabolique

Scheen, André

doi:10.1016/j.mmm.2023.05.006

Request a copy

Article (Scientific journals)

Traitement pharmacologique du diabète de type 2 après chirurgie bariatrique/métabolique

Scheen, André

2023 • In Médecine des Maladies Métaboliques, 17 (4), p. 351 - 357

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/305178

DOI
10.1016/j.mmm.2023.05.006

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

2023 MMM traitement après chir bariatrique.pdf

Author postprint (874.03 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Anti-hyperglycemic therapy; Bariatric surgery; Glucose-lowering agent; Metabolic surgery; Obesity; Type 2 diabetes

Abstract :

[en] Bariatric surgery has expanded in recent years with the development of metabolic surgery in patients with type 2 diabetes (T2D) and a body mass index < 35 kg/m2. The management of T2D after a gastric bypass or a sleeve gastrectomy requires some cautions, depending on the timing after the surgical procedure and the patient's evolution. Soon after the intervention, safety should be prioritized. So, gliflozins should be interrupted to avoid euglycemic diabetic ketoacidosis, while sulfonylureas should be stopped and insulin doses reduced to limit the risk of hypoglycemia. If a remission of T2D occurs, the maintenance of metformin or of a glucagon-like peptide-1 receptor agonist should be considered with the main objective to prolong the remission. Finally, if surgery fails to eradicate T2D or if a relapse occurs after a transient remission, the management of hyperglycemia should a priori follow the same rules as those used for patients with T2D who are not treated with bariatric/metabolic surgery. © 2023 Elsevier Masson SAS

Disciplines :

Endocrinology, metabolism & nutrition
Gastroenterology & hepatology
Pharmacy, pharmacology & toxicology

Author, co-author :

Scheen, André ; Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques

Language :

English

Title :

Traitement pharmacologique du diabète de type 2 après chirurgie bariatrique/métabolique

Alternative titles :

[en] Pharmacological therapy of type 2 diabetes following bariatric/metabolic surgery;

Publication date :

2023

Journal title :

Médecine des Maladies Métaboliques

ISSN :

1957-2557

eISSN :

2214-8477

Volume :

Issue :

Pages :

351 - 357

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 13 July 2023

Statistics

Number of views

29 (2 by ULiège)

Number of downloads

1 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

American Diabetes Association Professional Practice Committee, 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of medical care in diabetes-2022. Diabetes Care 45:Suppl. 1 (2022), S113–S124.
Vasdeki, D., Koufakis, T., Tsamos, G., et al. Remission as an emerging therapeutic target in type 2 diabetes in the era of new glucose-lowering agents: benefits, challenges, and treatment approaches. Nutrients, 14, 2022, 4801.
Zhou, X., Zeng, C., Diabetes remission of bariatric surgery and nonsurgical treatments in type 2 diabetes patients who failure to meet the criteria for surgery: a systematic review and meta-analysis. BMC Endocr Disord, 23, 2023, 46.
Rubino, F., Nathan, D.M., Eckel, R.H., et al. Delegates of the 2nd diabetes surgery summit. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care 39 (2016), 861–877.
Amouyal, C., Andreelli, F., Chirurgie métabolique du diabète de type 2. Med Mal Metab 9 (2015), 473–481.
Mulla, C.M., Baloch, H.M., Hafida, S., Management of diabetes in patients undergoing bariatric surgery. Curr Diab Rep, 19, 2019, 112.
Andreelli, A., La chirurgie bariatrique en 2015. Med Mal Metab 9 (2015), 465–499.
Andreelli, A., Chirurgie bariatrique : un autre regard. Med Mal Metab 13 (2019), 653–702.
Vouri, S.M., Chen, J., Sparkman, J., et al. Order of discontinuation of glucose-lowering medications following bariatric surgery. Diabetes Res Clin Pract, 172, 2021, 108580.
Aberle, J., Reining, F., Dannheim, V., et al. Metformin after bariatric surgery–an acid problem. Exp Clin Endocrinol Diabetes 120 (2012), 152–153.
Blanchot, A., Arbouche, N., Gheddar, L., et al. Bariatric surgery and changes in metformin distribution: about a fatal case. Toxicol Anal et Clin 34:3 Suppl. (2022), S79–S80.
Aminian, A., Kashyap, S.R., Burguera, B., et al. Incidence and clinical features of diabetic ketoacidosis after bariatric and metabolic surgery. Diabetes Care 39 (2016), e50–e53.
Thiruvenkatarajan, V., Meyer, E.J., Nanjappa, N., et al. Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review. Br J Anaesth 123 (2019), 27–36.
Gokhare Viswanath, N., Sharma, M., Bandlamudi, N., et al. Sodium-glucose co-transporter-2 inhibitors induced diabetic ketoacidosis in patients undergoing bariatric surgery: a systematic review of case reports and case series. Obes Surg 33 (2023), 339–344.
Rizo, I.M., Apovian, C.M., Diabetic ketoacidosis post bariatric surgery. Front Endocrinol (Lausanne), 9, 2018, 812.
Lane, S., Paskar, D., Hamed, S., Goffi, A., When guidelines fail: euglycemic diabetic ketoacidosis after bariatric surgery in a patient taking a sodium-glucose cotransporter-2 inhibitor: a case report. A A Pract 11 (2018), 46–48.
Sharma, M., Nayar, R., Graham, Y., et al. Risk of harm from use of sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients pre or post bariatric surgery. Obes Surg 32 (2022), 2469–2470.
Galtier, F., Pattou, F., Czernichow, S., DIAMS study group., et al. Bariatric surgery and the perioperative management of type 2 diabetes: practical guidelines. J Visc Surg 157 (2020), 13–21.
Scheen, A.J., Existe-t-il encore une place pour les sulfamides hypoglycémiants dans le traitement du diabète de type 2 en 2021 ?. Med Mal Metab 15 (2021), 45–52.
Preda, V., Khoo, S.S., Preda, T., Lord, R.V., Gastroparesis with bezoar formation in patients treated with glucagon-like peptide-1 receptor agonists: potential relevance for bariatric and other gastric surgery. BJS Open, 7, 2023, zrac169.
Gorgojo-Martínez, J.J., Mezquita-Raya, P., Carretero-Gómez, J., et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med, 12, 2022, 145.
Kassel, L.E., Berei, J.J., Pitlick, J.M., Rand, J.E., Insulin dose adjustment following bariatric surgery, a review of available literature. J Diabetes Sci Technol 16 (2022), 1560–1566.
Tsilingiris, D., Koliaki, C., Kokkinos, A., Remission of type 2 diabetes mellitus after bariatric surgery: fact or fiction?. Int J Environ Res Public Health, 16, 2019, 3171.
Riddle, M.C., Cefalu, W.T., Evans, P.H., et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetologia 64 (2021), 2359–2366.
Fultang, J., Chinaka, U., Rankin, J., et al. Preoperative bariatric surgery predictors of type 2 diabetes remission. J Obes Metab Syndr 30 (2021), 104–114.
Stenberg, E., Olbers, T., Cao, Y., et al. Factors determining chance of type 2 diabetes remission after Roux-en-Y gastric bypass surgery: a nationwide cohort study in 8057 Swedish patients. BMJ Open Diabetes Res Care, 9, 2021, e002033.
Yu, Z., Li, P., Li, P., et al. Meta-analysis of long-term relapse rate of type 2 diabetes following initial remission after Roux-en-Y gastric bypass. Obes Surg 31 (2021), 5034–5043.
Sudlow, A., Pournaras, D.J., le Roux, C.W., Combining metabolic surgery with medications for type 2 diabetes: is there a benefit?. J Bariatr Surg 2 (2023), 13–19.
Sudlow, A., le Roux, C.W., Pournaras, D.J., Review of multimodal treatment for type 2 diabetes: combining metabolic surgery and pharmacotherapy. Ther Adv Endocrinol Metab, 10, 2019 [2042018819875407].
American Diabetes Association, 5. Prevention or delay of type 2 diabetes: standards of medical care in diabetes-2018. Diabetes Care 41:Suppl. 1 (2018), S51–S54.
Mori, Y., Duru, O.K., Tuttle, K.R., et al. Sodium-glucose cotransporter 2 inhibitors and new-onset type 2 diabetes in adults with prediabetes: systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 108 (2022), 221–231.
Holst, J.J., Madsbad, S., Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor. Surg Obes Relat Dis 12 (2016), 1236–1242.
Hutch, C.R., Sandoval, D., The role of GLP-1 in the metabolic success of bariatric surgery. Endocrinology 158 (2017), 4139–4151.
le Roux, C.W., Astrup, A., Fujioka, K., SCALE Obesity Prediabetes NN8022-1839 Study Group., et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 389 (2017), 1399–1409 [Erratum in: Lancet 2017; 389:1398].
Perreault, L., Davies, M., Frias, J.P., et al. Changes in glucose metabolism and glycemic status with once-weekly subcutaneous semaglutide 2.4 mg among participants with prediabetes in the STEP Program. Diabetes Care 45 (2022), 2396–2405.
Jans, A., Szabo, E., Näslund, I., et al. Factors affecting relapse of type 2 diabetes after bariatric surgery in Sweden 2007–2015: a registry-based cohort study. Surg Obes Relat Dis 18 (2022), 305–312.
Mingrone, G., Treatment of persistent or recurrent type 2 diabetes after metabolic surgery. Lancet Diabetes Endocrinol 7 (2019), 504–505.
Padwal, R.S., Gabr, R.Q., Sharma, A.M., et al. Effect of gastric bypass surgery on the absorption and bioavailability of metformin. Diabetes Care 34 (2011), 1295–1300.
Lorico, S., Colton, B., Medication management and pharmacokinetic changes after bariatric surgery. Can Fam Physician 66 (2020), 409–416.
Bonnet, F., Scheen, A., Understanding and overcoming metformin gastrointestinal intolerance. Diabetes Obes Metab 19 (2017), 473–481.
Shah, A., Levesque, K., Pierini, E., et al. Effect of sitagliptin on glucose control in type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery. Diabetes Obes Metab 20 (2018), 1018–1023.
Kheniser, K., Kashyap, S.R., Canagliflozin versus placebo for post-bariatric surgery patients with persistent type II diabetes: a randomized controlled trial (CARAT). Diabetes Obes Metab 19 (2017), 609–610.
Kashyap, S.R., Kheniser, K., Aminian, A., et al. Double-blinded, randomized, and controlled study on the effects of canagliflozin after bariatric surgery: a pilot study. Obes Sci Pract 6 (2020), 255–263 [eCollection 2020 June].
Eisenberg, D., Azagury, D.E., Ghiassi, S., et al. ASMBS position statement on postprandial hyperinsulinemic hypoglycemia after bariatric surgery. Surg Obes Relat Dis 13 (2017), 371–378.
Ritz, P., Vaurs, C., Barigou, M., Hanaire, H., Hypoglycémie après bypass gastrique : mise au point au sujet des mécanismes et des traitements. Med Mal Metab 9 (2015), 482–487.
Ciudin, A., Sánchez, M., Hernandez, I., et al. Canagliflozin: a new therapeutic option in patients that present postprandial hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass: a pilot study. Obes Facts 14 (2021), 291–297.
Beshyah, S.A., First beneficial use of dapagliflozin for treatment of post-bariatric hypoglycemia: case report and hypothesis. Ibnosina J Med BS 8 (2016), 335–342.
Carpentieri, G.B., Goncalves, S.E., Casagrande, M.Z., et al. SGLT2 inhibition with empagliflozin as a possible therapeutic option for postprandial hypoglycemia after bariatric surgery. Obes Surg 32 (2022), 2664–2671.
Ferreira, A., Emara, A.F., Herzig, D., et al. Study protocol for a randomised, double-blind, placebo-controlled crossover trial assessing the impact of the SGLT2 inhibitor empagliflozin on postprandial hypoglycaemia after gastric bypass. BMJ Open, 12, 2022, e060668.
Hepprich, M., Wiedemann, S.J., Schelker, B.L., et al. Postprandial hypoglycemia in patients after gastric bypass surgery is mediated by glucose-induced IL-1β. Cell Metab 31 (2020), 699–709 [e5].
Llewellyn, D.C., Logan Ellis, H., Aylwin, S.J., et al. The efficacy of GLP-1RAs for the management of postprandial hypoglycemia following bariatric surgery: a systematic review. Obesity (Silver Spring) 31 (2023), 20–30.
Almby, K.E., Abrahamsson, N., Lundqvist, M.H., et al. Effects of GLP-1 on counter-regulatory responses during hypoglycemia after GBP surgery. Eur J Endocrinol 181 (2019), 161–171.
Gazda, C.L., Clark, J.D., Lingvay, I., Almandoz, J.P., Pharmacotherapies for post-bariatric weight regain: real-world comparative outcomes. Obesity (Silver Spring) 29 (2021), 829–836 [Erratum in: Obesity (Silver Spring) 2021; 29:1567].
Redmond, I.P., Shukla, A.P., Aronne, L.J., Use of weight loss medications in patients after bariatric surgery. Curr Obes Rep 10 (2021), 81–89.
Vilsbøll, T., Christensen, M., Junker, A.E., et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ, 344, 2012, d7771.
Sarma, S., Palcu, P., Weight loss between glucagon-like peptide-1 receptor agonists and bariatric surgery in adults with obesity: a systematic review and meta-analysis. Obesity (Silver Spring) 30 (2022), 2111–2121.
Jensen, A.B., Renström, F., Aczél, S., et al. Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery-a retrospective observational study. Obes Surg 33 (2023), 1017–1025.
Lautenbach, A., Wernecke, M., Huber, T.B., et al. The potential of semaglutide once-weekly in patients without type 2 diabetes with weight regain or insufficient weight loss after bariatric surgery-a retrospective analysis. Obes Surg 32 (2022), 3280–3288.
Horber, F.F., Steffen, R., Reversal of long-term weight regain after Roux-en-Y gastric bypass using liraglutide or surgical revision. A prospective study. Obes Surg 31 (2021), 93–100 [Erratum in: Obes Surg 2021; 31:3386].
Thakur, U., Bhansali, A., Gupta, R., Rastogi, A., Liraglutide augments weight loss after laparoscopic sleeve gastrectomy: a randomised, double-blind, placebo-control study. Obes Surg 31 (2021), 84–92.
Wharton, S., Kuk, J.L., Luszczynski, M., et al. Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery. Clin Obes, 9, 2019, e12323 [Erraum in: Clin Obes 2019; 9:e12338].
Muratori, F., Vignati, F., Di Sacco, G., et al. Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery. Eat Weight Disord 27 (2022), 2775–2781.
Elhag, W., El Ansari, W., Effectiveness and safety of liraglutide in managing inadequate weight loss and weight regain after primary and revisional bariatric surgery: anthropometric and cardiometabolic outcomes. Obes Surg 32 (2022), 1005–1015.
Tang, T., Abbott, S., le Roux, C.W., et al. Preoperative weight loss with glucagon-like peptide-1 receptor agonist treatment predicts greater weight loss achieved by the combination of medical weight management and bariatric surgery in patients with type 2 diabetes: A longitudinal analysis. Diabetes Obes Metab 20 (2018), 745–748.
Gorgojo-Martínez, J.J., Feo-Ortega, G., Serrano-Moreno, C., Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery. Surg Obes Relat Dis 12 (2016), 1856–1863.
Miras, A.D., Pérez-Pevida, B., Aldhwayan, M., et al. Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 7 (2019), 549–559.
Scheen, A.J., Dual GIP/GLP-1 receptor agonists: new advances for treating type 2-diabetes. Ann Endocrinol (Paris) 84 (2023), 316–321.
Scheen, A.J., Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 16 (2020), 556–577.
Scheen, A.J., Use of SGLT2 inhibitors after bariatric/metabolic surgery: risk/benefit balance. Diabetes Metab, 2023 [In press].